Copyright Reports & Markets. All rights reserved.

Global Retinal Biosimilars Market Size, Status and Forecast 2019-2025

Request for Sample of this report
Buy now

Table of Contents

    1 Report Overview

    • 1.1 Study Scope
    • 1.2 Key Market Segments
    • 1.3 Players Covered
    • 1.4 Market Analysis by Type
      • 1.4.1 Global Retinal Biosimilars Market Size Growth Rate by Type (2014-2025)
      • 1.4.2 Macular Degeneration Drugs
      • 1.4.3 Diabetic Eye Disease Drugs
      • 1.4.4 Macular Pucker Drugs
      • 1.4.5 Others
    • 1.5 Market by Application
      • 1.5.1 Global Retinal Biosimilars Market Share by Application (2014-2025)
      • 1.5.2 Hospital Pharmacies
      • 1.5.3 Retail Pharmacies
      • 1.5.4 Online Pharmacies
    • 1.6 Study Objectives
    • 1.7 Years Considered

    2 Global Growth Trends

    • 2.1 Retinal Biosimilars Market Size
    • 2.2 Retinal Biosimilars Growth Trends by Regions
      • 2.2.1 Retinal Biosimilars Market Size by Regions (2014-2025)
      • 2.2.2 Retinal Biosimilars Market Share by Regions (2014-2019)
    • 2.3 Industry Trends
      • 2.3.1 Market Top Trends
      • 2.3.2 Market Drivers
      • 2.3.3 Market Opportunities

    3 Market Share by Key Players

    • 3.1 Retinal Biosimilars Market Size by Manufacturers
      • 3.1.1 Global Retinal Biosimilars Revenue by Manufacturers (2014-2019)
      • 3.1.2 Global Retinal Biosimilars Revenue Market Share by Manufacturers (2014-2019)
      • 3.1.3 Global Retinal Biosimilars Market Concentration Ratio (CR5 and HHI)
    • 3.2 Retinal Biosimilars Key Players Head office and Area Served
    • 3.3 Key Players Retinal Biosimilars Product/Solution/Service
    • 3.4 Date of Enter into Retinal Biosimilars Market
    • 3.5 Mergers & Acquisitions, Expansion Plans

    4 Breakdown Data by Type and Application

    • 4.1 Global Retinal Biosimilars Market Size by Type (2014-2019)
    • 4.2 Global Retinal Biosimilars Market Size by Application (2014-2019)

    5 United States

    • 5.1 United States Retinal Biosimilars Market Size (2014-2019)
    • 5.2 Retinal Biosimilars Key Players in United States
    • 5.3 United States Retinal Biosimilars Market Size by Type
    • 5.4 United States Retinal Biosimilars Market Size by Application

    6 Europe

    • 6.1 Europe Retinal Biosimilars Market Size (2014-2019)
    • 6.2 Retinal Biosimilars Key Players in Europe
    • 6.3 Europe Retinal Biosimilars Market Size by Type
    • 6.4 Europe Retinal Biosimilars Market Size by Application

    7 China

    • 7.1 China Retinal Biosimilars Market Size (2014-2019)
    • 7.2 Retinal Biosimilars Key Players in China
    • 7.3 China Retinal Biosimilars Market Size by Type
    • 7.4 China Retinal Biosimilars Market Size by Application

    8 Japan

    • 8.1 Japan Retinal Biosimilars Market Size (2014-2019)
    • 8.2 Retinal Biosimilars Key Players in Japan
    • 8.3 Japan Retinal Biosimilars Market Size by Type
    • 8.4 Japan Retinal Biosimilars Market Size by Application

    9 Southeast Asia

    • 9.1 Southeast Asia Retinal Biosimilars Market Size (2014-2019)
    • 9.2 Retinal Biosimilars Key Players in Southeast Asia
    • 9.3 Southeast Asia Retinal Biosimilars Market Size by Type
    • 9.4 Southeast Asia Retinal Biosimilars Market Size by Application

    10 India

    • 10.1 India Retinal Biosimilars Market Size (2014-2019)
    • 10.2 Retinal Biosimilars Key Players in India
    • 10.3 India Retinal Biosimilars Market Size by Type
    • 10.4 India Retinal Biosimilars Market Size by Application

    11 Central & South America

    • 11.1 Central & South America Retinal Biosimilars Market Size (2014-2019)
    • 11.2 Retinal Biosimilars Key Players in Central & South America
    • 11.3 Central & South America Retinal Biosimilars Market Size by Type
    • 11.4 Central & South America Retinal Biosimilars Market Size by Application

    12 International Players Profiles

    • 12.1 Novartis (Sandoz)
      • 12.1.1 Novartis (Sandoz) Company Details
      • 12.1.2 Company Description and Business Overview
      • 12.1.3 Retinal Biosimilars Introduction
      • 12.1.4 Novartis (Sandoz) Revenue in Retinal Biosimilars Business (2014-2019)
      • 12.1.5 Novartis (Sandoz) Recent Development
    • 12.2 Shire
      • 12.2.1 Shire Company Details
      • 12.2.2 Company Description and Business Overview
      • 12.2.3 Retinal Biosimilars Introduction
      • 12.2.4 Shire Revenue in Retinal Biosimilars Business (2014-2019)
      • 12.2.5 Shire Recent Development
    • 12.3 Bayer
      • 12.3.1 Bayer Company Details
      • 12.3.2 Company Description and Business Overview
      • 12.3.3 Retinal Biosimilars Introduction
      • 12.3.4 Bayer Revenue in Retinal Biosimilars Business (2014-2019)
      • 12.3.5 Bayer Recent Development
    • 12.4 Genentech
      • 12.4.1 Genentech Company Details
      • 12.4.2 Company Description and Business Overview
      • 12.4.3 Retinal Biosimilars Introduction
      • 12.4.4 Genentech Revenue in Retinal Biosimilars Business (2014-2019)
      • 12.4.5 Genentech Recent Development
    • 12.5 Pfenex
      • 12.5.1 Pfenex Company Details
      • 12.5.2 Company Description and Business Overview
      • 12.5.3 Retinal Biosimilars Introduction
      • 12.5.4 Pfenex Revenue in Retinal Biosimilars Business (2014-2019)
      • 12.5.5 Pfenex Recent Development
    • 12.6 Reliance Life Sciences
      • 12.6.1 Reliance Life Sciences Company Details
      • 12.6.2 Company Description and Business Overview
      • 12.6.3 Retinal Biosimilars Introduction
      • 12.6.4 Reliance Life Sciences Revenue in Retinal Biosimilars Business (2014-2019)
      • 12.6.5 Reliance Life Sciences Recent Development
    • 12.7 Hetero Drugs
      • 12.7.1 Hetero Drugs Company Details
      • 12.7.2 Company Description and Business Overview
      • 12.7.3 Retinal Biosimilars Introduction
      • 12.7.4 Hetero Drugs Revenue in Retinal Biosimilars Business (2014-2019)
      • 12.7.5 Hetero Drugs Recent Development
    • 12.8 Intas Pharmaceuticals
      • 12.8.1 Intas Pharmaceuticals Company Details
      • 12.8.2 Company Description and Business Overview
      • 12.8.3 Retinal Biosimilars Introduction
      • 12.8.4 Intas Pharmaceuticals Revenue in Retinal Biosimilars Business (2014-2019)
      • 12.8.5 Intas Pharmaceuticals Recent Development
    • 12.9 Santo Holding
      • 12.9.1 Santo Holding Company Details
      • 12.9.2 Company Description and Business Overview
      • 12.9.3 Retinal Biosimilars Introduction
      • 12.9.4 Santo Holding Revenue in Retinal Biosimilars Business (2014-2019)
      • 12.9.5 Santo Holding Recent Development
    • 12.10 Regeneron Pharmaceuticals
      • 12.10.1 Regeneron Pharmaceuticals Company Details
      • 12.10.2 Company Description and Business Overview
      • 12.10.3 Retinal Biosimilars Introduction
      • 12.10.4 Regeneron Pharmaceuticals Revenue in Retinal Biosimilars Business (2014-2019)
      • 12.10.5 Regeneron Pharmaceuticals Recent Development

    13 Market Forecast 2019-2025

    • 13.1 Market Size Forecast by Regions
    • 13.2 United States
    • 13.3 Europe
    • 13.4 China
    • 13.5 Japan
    • 13.6 Southeast Asia
    • 13.7 India
    • 13.8 Central & South America
    • 13.9 Market Size Forecast by Product (2019-2025)
    • 13.10 Market Size Forecast by Application (2019-2025)

    14 Analyst's Viewpoints/Conclusions

      15 Appendix

      • 15.1 Research Methodology
        • 15.1.1 Methodology/Research Approach
          • 15.1.1.1 Research Programs/Design
          • 15.1.1.2 Market Size Estimation
          • 12.1.1.3 Market Breakdown and Data Triangulation
        • 15.1.2 Data Source
          • 15.1.2.1 Secondary Sources
          • 15.1.2.2 Primary Sources
      • 15.2 Disclaimer

      In 2018, the global Retinal Biosimilars market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2019-2025.

      This report focuses on the global Retinal Biosimilars status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Retinal Biosimilars development in United States, Europe and China.

      The key players covered in this study
      Novartis (Sandoz)
      Shire
      Bayer
      Genentech
      Pfenex
      Reliance Life Sciences
      Hetero Drugs
      Intas Pharmaceuticals
      Santo Holding
      Regeneron Pharmaceuticals

      Market segment by Type, the product can be split into
      Macular Degeneration Drugs
      Diabetic Eye Disease Drugs
      Macular Pucker Drugs
      Others

      Market segment by Application, split into
      Hospital Pharmacies
      Retail Pharmacies
      Online Pharmacies

      Market segment by Regions/Countries, this report covers
      United States
      Europe
      China
      Japan
      Southeast Asia
      India
      Central & South America

      The study objectives of this report are:
      To analyze global Retinal Biosimilars status, future forecast, growth opportunity, key market and key players.
      To present the Retinal Biosimilars development in United States, Europe and China.
      To strategically profile the key players and comprehensively analyze their development plan and strategies.
      To define, describe and forecast the market by product type, market and key regions.

      In this study, the years considered to estimate the market size of Retinal Biosimilars are as follows:
      History Year: 2014-2018
      Base Year: 2018
      Estimated Year: 2019
      Forecast Year 2019 to 2025
      For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

      Buy now